Friday, May 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

The cost structure of hospitals nearly doubles

Summary

This episode of the Daily Remedy Podcast explores the significant impact of geopolitical conflicts, particularly in the Middle East, on healthcare costs in the United States. The discussion highlights how fluctuations in oil prices affect various aspects of healthcare, including hospital operating costs, the production of medical supplies, pharmaceuticals, and logistics. The episode emphasizes the pervasive role of oil in the healthcare industry and the potential consequences of rising oil prices on patient care and healthcare affordability.

Takeaways

The geopolitical conflict in the Middle East has far-reaching implications for healthcare costs in the U.S.
Oil prices directly influence the operational costs of hospitals.
Healthcare CFOs are budgeting for energy volatility due to oil price fluctuations.
A significant portion of medical supplies is derived from petroleum-based products.
Rising oil prices lead to increased costs for pharmaceuticals and medical devices.
Logistics and transportation costs in healthcare are heavily impacted by oil prices.
Healthcare’s dependency on oil makes it vulnerable to price spikes.
The cost of energy is a major driver of healthcare expenses.
Increased oil prices can lead to higher patient costs and deductibles.
Understanding the connection between oil and healthcare is crucial for future planning.

 

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!